Endpoint News: FDA loosens safety requirements for CAR-Ts in move to boost access
BioPharm Dive: RFK Jr.-appointed panel recommends flu shots be free of contested preservative
Endpoint News: CEOs push EU to include cell, gene therapy incentives in Biotech Act
Endpoint News: Inside the FDA’s ‘listening’ tour: Officials agree US lags behind China on drug development
Fierce Pharma: UCB plots regulatory filings as Fintepla shows potential to treat a 3rd epilepsy disorder
Fierce Biotech: Hummingbird uses VISTA buzz to secure $290M pact for tumor drug
Endpoint News: Innovent brings a new mechanism to obesity market with China approval
MIT Technology Review: Google’s new AI will help researchers understand how our genes work
A few of the key pain points we heard over and over from conversations with attendees included:
Bandwidth constraints are limiting BD teams’ ability to deeply analyze assets.
It’s an immense challenge for stakeholders (whether internal management, investors, or analysts) to maintain a comprehensive, real-time understanding of the many moving parts in a biopharma company's or the broader industry's drug development efforts, particularly given the critical and often unpredictable nature of key events that drive value.Language barriers complicate tracking global programs.
Many teams struggle to monitor overseas programs from China, Japan, and Korea because standard databases rely on patchy public data.Siloed data across disconnected systems hinders a holistic market view.
A lot of manual work goes into using the current databases. Just staying on top of all the subscriptions is a challenge, and teams need to pull information and assets on an ongoing basis, such as scientific publications, clinical trial results, regulatory updates, market reports, and competitor intelligence. The problem isn't just the quantity; it's also that this information often lives in disconnected databases and systems. This creates silos, making it incredibly difficult to get a holistic view of a drug's development, market landscape, or even the broader scientific progress.
Vibe Bio is building the technology that helps biopharmas overcome these challenges. Want to learn about how VibeOne enables BD&L teams to stay ahead? Get in touch.
We recently spoke with Shalini Sharp — a powerhouse board member (BeiGene, Septerna, Neurcrine Biosciences, Organon, and Mahzi Therapeutics) and former biotech CFO (Ultragenyx Pharmaceuticals, Inc. and Agenus) — about how to build and prioritize a winning pharma portfolio.
Key takeaways:
1. Start with a clear strategic vision.
Effective prioritization in biopharma begins with a long-term strategic vision (5-20 years out). This vision then guides current plans, ensuring disciplined decisions on asset prioritization, balancing patient impact, and financial viability.
2. Evaluate assets holistically and objectively.
When building a portfolio, thoroughly assess assets using a wide range of factors, not just scientific promise. Consider patient need, competitive landscape, manufacturability, market opportunity, and financial modeling. Objectivity is key; all assets should be compared fairly, whether internally developed or in-licensed.
3. Embrace disciplined decision-making and cross-functional collaboration.
Despite emotional attachments to programs, leaders must be willing to walk away when data doesn't support a project. The best decisions come from cross-functional teams that break down silos. Setting clear, data-driven "go/no-go" criteria upfront is crucial to combat bias and align with the mission.
Read the blog post to learn more about navigating pharma strategy and portfolio prioritization.
When we talk to teams on the front lines of drug development, some themes keep popping up:
Difficulty pursuing unconventional launches (e.g., GLP-1 obesity repositioning)
Pushback from lower-level teams on innovative tools
Balancing biological plausibility with commercial viability
Lack of scalable, automated systems to analyze diverse assets
They see generative AI as a way to streamline workflows, speed up decision-making, and better integrate biological and commercial strategy, particularly for early-phase asset evaluation. But adoption challenges remain as teams figure out how to integrate AI-powered analysis into their processes.
If you’ve read our newsletter before, you heard that we use Discord to stay connected. We recently moved our day-to-day from Discord to Slack — a more structured, secure space that better fits our mission-driven collaboration.
And speaking of team news: Lulu the Airedale joined one of us for a few days, delighting (and slightly terrorizing) everyone.
We believe communities spark cures — let’s stay connected as we build the future together.
Tell us what else you’d like to see in future editions of the newsletter. We’d love to hear from you!
Sincerely,
The Vibe Bio Team
#EveryCureforEveryCommunity
Subscribe to our newsletter
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.